We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Whole Genetic Code of IVF Embryos Scanned for Mutations

By LabMedica International staff writers
Posted on 23 Feb 2015
Currently, the methods available for preimplantation genetic diagnosis (PGD) of in vitro fertilized (IVF) embryos do not detect de novo single-nucleotide and short indel mutations, which have been shown to cause a large fraction of genetic diseases.

The detection and phasing of single base de novo mutations in biopsies from human in vitro fertilized embryos by advanced whole-genome sequencing has been accomplished and the technique would enable couples to use IVF for the conception of children who otherwise would have inherited devastating mitochondrial diseases.

Genomic scientists at Complete Genomics, Inc. More...
(Mountain View, CA, USA) and their colleagues used a new technique that allows the whole genome of IVF embryos to be scanned via the cells of 10 biopsies. The team said the testing is the first to be able to detect all the new genetic mutations that happen uniquely in an individual, as opposed to only those that have been handed down from parents.

Using up to just 10 cells to do the whole-genome sequencing means the DNA has to be amplified, which can introduce errors. However, the scientists working with another commercial team from Reprogenetics (Livingston, NJ, USA), used the technique at a fertility center to remove any falsely identified genetic mutations. They applied their "long fragment read" technology, using DNA barcodes to assign DNA fragments to the embryos' maternal or paternal genome. They were able to remove over 100,000 sequencing errors, reducing the error rate approximately 100-fold over previous studies.

The technique means the 5-day-old, blastocyst-stage embryos could be scanned for de novo mutations, those arising spontaneously in the egg or sperm and not inherited from either parent. In one embryo in the study, the scientists did not find any de novo mutations in the regions of the genome that code for proteins. In the other embryo from the couple, however, they picked up two coding mutations in the zinc finger protein 266 (ZNF266) and the solute carrier family 26, (SLC26A10) genes that may be potentially damaging.

The authors concluded that the biggest hurdle now is one of how to analyze the medical impact of detected mutations and make decisions based on those results. Whole-genome sequencing using barcoded DNA could be used in the future as part of the preimplantation genetic diagnosis process to maximize comprehensiveness in detecting disease-causing mutations and reduce the incidence of genetic diseases. The study was published on February 11, 2015, in the journal Genome Research.

Related Links:

Complete Genomics, Inc.
Reprogenetics 



Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Pipette Controller
Sapphire MaxiPette
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.